Back to results
US 2026/0083742 A1Published application
Homologous recombination repair deficiency (hrd) as a predictive biomarker for treating cancer with wee1 inhibitors
AssigneeZeno Management, Inc.
InventorsJianhui Ma, Olivier Harismendy, Jiali Li, Ahmed Abdi Samatar, Samuel DePrimo, Catherine Lee, Monah Abed
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, among other things, methods for treating cancer comprising administering an effective dose of azenosertib, or a pharmaceutically acceptable salt thereof, to subjects selected to have a homologous recombination repair deficiency (HRD).
Claims76
A method of treating cancer comprising:
- administering an effective dose of azenosertib, or a pharmaceutically acceptable salt thereof, to a subject selected to have a cancer with a homologous recombination repair deficiency (HRD).
A method of treating cancer comprising:
- administering an effective dose of azenosertib, or a pharmaceutically acceptable salt thereof, to a subject selected to have a cancer with a homologous recombination repair deficiency-positive (HRD-positive or HRD+) status.
A method of treating a cancer comprising:
- determining or having determined whether a subject has a homologous repair deficiency (HRD) or a HRD-positive (HRD+) status;
- and
- if the subject has the HRD or the HRD-positive (HRD+) status, administering an effective dose of azenosertib, or a pharmaceutically acceptable salt thereof, to the subject;
- wherein the administration of azenosertib, or a pharmaceutically acceptable salt thereof, results in the inhibition of the cancer in the subject.
1 more element
A method of treating PARP inhibitor-resistant breast cancer comprising:
- determining or having determined whether a subject has a homologous repair deficiency (HRD) or a HRD-positive (HRD+) status;
- and
- if the subject has the HRD or the HRD-positive (HRD+) status, administering an effective dose of azenosertib, or a pharmaceutically acceptable salt thereof, to the subject;
- wherein the administration of azenosertib, or a pharmaceutically acceptable salt thereof, results in the inhibition of the cancer in the subject.
1 more element
A method of treating chemotherapy-resistant ovarian cancer comprising:
- determining or having determined whether a subject has a homologous repair deficiency (HRD) or a HRD-positive (HRD+) status;
- and
- if the subject has the HRD or the HRD-positive (HRD+) status, administering an effective dose of azenosertib, or a pharmaceutically acceptable salt thereof, to the subject;
- wherein the administration of azenosertib, or a pharmaceutically acceptable salt thereof, results in the inhibition of the cancer in the subject.
1 more element
Dependencies are inferred from the claim text.